Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
Myriad Genetics has launched Prolaris + AI, a novel prostate cancer diagnostic test that integrates molecular biomarker data with AI-driven digital pathology to better assess prostate cancer aggressiveness and personalize active surveillance plans. This innovative test enhances prognostic accuracy by combining traditional molecular scoring with an …